CKD-519

Research use only, not for human use.

CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.

CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM; exhibites a maximum of 70%-86% inhibition of CETP activity and 25%-48% increase of HDL-C levels after two weeks of oral administration of 1, 3, or 10 mg/kg in transgenic mice expressing human CETP/apolipoprotein AI; CKD-519 (Rocacetrapib, CKD519) is being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.Dyslipidemia Phase 2 Clinical.

——

——

Rocacetrapib | CKD519

Metabolic Enzyme/Protease

CETP

CETP

Cardiovascular Disease

Dyslipidemia

1402796-27-3

601.606

C31H34F7NO3

>98% (HPLC)

In Vitro:?DMSO : 66.67 mg/mL (110.82 mM)

C[C@H]1[C@@H](C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)OC(N1CC3=C(CCC(C)(C)C3)C4=C(OC)C=C(F)C(C(C)C)=C4)=O

(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5,5-dimethylcyclohex-1-en-1-yl}methyl)-4-methyl-1,3-oxazolidin-2-one

(-20℃)

With Ice Pack

≥ 2 years